Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
StockNews.AI · 3 hours
AI Summary
Hemab presented HMB-002 data in Von Willebrand Disease showing dose-dependent increases in VWF and FVIII (≥2.4x at 150 mg) with a PK/PD profile suggesting monthly subcutaneous dosing. The company also unveiled HMB-003, a non-hormonal plasmin inhibitor with extended antifibrinolytic activity for heavy menstrual bleeding. ISTH 2026 could provide near-term momentum if early signals translate into durable clinical benefits.
Sentiment Rationale
Positive early data (≥2.4x VWF/FVIII, PK/PD with monthly dosing) and the HMB-003 program may shift sentiment toward Hemab's pipeline; however, small sample size and reliance on early-stage data keep upside guarded until larger trials confirm durability and safety.
Trading Thesis
Near-term upside for COAG if HMB-002 data translate to durable VWD control; monitor Phase 2/3 timelines over the next 3–6 months.
Market-Moving
- HMB-002 data imply durable VWD control and potential monthly dosing.
- 8 of 9 evaluable patients had zero bleeds in 28 days post-dosing.
- HMB-003 expands antifibrinolytic pipeline with extended activity.
- ISTH 2026 conference provides near-term visibility for Hemab programs.
Key Facts
- HMB-002 in VWD shows ≥2.4x VWF and FVIII increases; PK/PD supports monthly dosing.
- Safety profile is favorable; no serious TEAEs or thromboembolic events; no discontinuations.
- HMB-003 announced as non-hormonal plasmin inhibitor with extended antifibrinolytic activity.
- ISTH 2026 Paris presentations highlight HMB-002 data and HMB-003 program.
Companies Mentioned
- Hemab Therapeutics (COAG): Presented HMB-002 VWD data and announced HMB-003 program; potential first-in-class prophylaxis.
- Barts Health NHS Trust (N/A): Clinician remarks support potential paradigm shift in VWD treatment via HMB-002.
- ISTH (N/A): Conference vehicle for data release; catalysts for investor attention.
Industry News
Industry News. The update highlights a pivotal data read for a first-in-class VWD approach and a complementary antifibrinolytic; success depends on later-stage efficacy and safety milestones.